By Sherry Qin
A biotech company and a metals processor made their Hong Kong debuts Friday, as the Asian financial hub's initial public offering market starts the year on a strong footing after reclaiming its position as the world's top fundraising venue in 2025.
Shares of Suzhou Ribo Life Science's shares rose 21% to HK$70.25 in early trading from their listing price of HK$57.97. The company, which develops small nucleic acid drugs, raised HK$1.83 billion, equivalent to US$234.8 million.
Yunnan Jinxun Resources, a Chinese non-ferrous metal processor, raised HK$1.10 billion in gross proceeds by selling 36.8 million shares. The company, which operates copper smelters in Africa, saw its shares climb 22% to HK$36.68 on Friday.
Hong Kong's IPO market has maintained its momentum in the new year after reclaiming the top global spot for capital raised in 2025. The city raised HK$285.8 billion in 2025, a 225% increase from 2024, according to HKEX data.
The two listings add to a growing roster of Chinese companies--from artificial-intelligence startups to chip makers--turning to Hong Kong's capital market to fund expansion.
Hong Kong's IPO market could raise up to HK$350 billion in 2026, supported by listings from high-end manufacturing and technology companies, said Eddie Wong, PwC Hong Kong's capital markets leader.
Wong expects new listings to become more diversified, with companies across sectors seeking funding tied to innovation and technology.
Write to Sherry Qin at sherry.qin@wsj.com
(END) Dow Jones Newswires
January 08, 2026 22:08 ET (03:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.